Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Macy's Inc (M) Price & Performance

Abeona Therapeutics IncTrade
Macy's IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Macy's Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Macy's Inc trades at $24.57 (market cap $6.68B). The key difference: Macy's Inc is far larger — about 15.7× Abeona Therapeutics Inc's market cap, and Macy's Inc pays a 3.02% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOM
Market Cap
$424.33M$6.68B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$26.21
52-Week Low
$4.17$12.73
Enterprise Value
$279.23M$10.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Macy's Inc

Macy's (M) trades at $25.40, up 1.07% daily, with a bullish technical signal and positive earnings momentum after beating estimates in three consecutive quarters. The stock shows attractive valuation with a P/E of 10.5 and P/S of 0.31, while recent news highlights institutional buying and turnaround progress under the 'Bold New Chapter' strategy.

Outlook is cautiously optimistic with potential upside to the $30 analyst high target, supported by cost discipline and store revamps. Risks include competitive retail pressures and consumer spending volatility, but solid cash flow and low debt provide stability. The stock offers value with a 2.94% net margin and 14.36% ROE.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M